Phase II Single Arm Study of CABozantinib in Non-Small Cell Lung Cancer Patients with MET Deregulation (CABinMET)

被引：5
|
作者：
D'Arcangelo, M. [1 ]
Tassinari, D. [2 ]
De Marinis, F. [3 ]
Delmonte, A. [4 ]
Galetta, D. [5 ]
Cecere, F. [6 ]
Pilotto, S. [7 ]
Zanelli, F. [8 ]
Bonanno, L. [9 ]
Landi, L. [1 ]
D'Inca, F. [10 ]
Cappuzzo, F. [1 ]
机构：
[1] Azienda Usl Romagna, Oncol & Hematol, Ravenna, Italy
[2] Ausl Romagna, Rimini, Italy
[3] Ist Europeo Oncol Ircss, Milan, Italy
[4] Ist Sci Romagnolo Studio & Cura Tumori Irst, Meldola, Italy
[5] Clin Canc Ctr Giovanni Paolo Ii, Thorac Med Oncol Unit, Bari, Italy
[6] Ist Nazl Tumori Regina Elena, Rome, Italy
[7] Aou Integrata Verona, Verona, Italy
[8] Arcispedale Santa Maria Nuova, Reggio Emilia, Italy
[9] Ist Oncol Veneto, Padua, Italy
[10] Fdn Ric Traslaz, Rome, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
NSCLC; MET; cabozantinib;
D O I：
10.1016/j.jtho.2019.08.1359
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.01-15
引用
收藏
页码：S644 / S644
页数：1
相关论文
共 50 条
  • [1] A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer
    Hisashi Tanaka
    Kageaki Taima
    Takeshi Morimoto
    Yoshihito Tanaka
    Masamichi Itoga
    Kunihiko Nakamura
    Akihito Hayashi
    Mika Kumagai
    Hideo Yasugahira
    Megumi Mikuniya
    Koichi Okudera
    Shingo Takanashi
    Sadatomo Tasaka
    BMC Cancer, 17
  • [2] Single-Arm Phase II Study of Nab-Paclitaxel for Patients with Chemorefractory Non-Small Cell Lung Cancer
    Tanaka, Hisashi
    Taima, Kageaki
    Morimoto, Takeshi
    Tanaka, Yoshihito
    Itoga, Masamichi
    Nakamura, Kunihiko
    Hayashi, Akihito
    Kumagai, Mika
    Yasugahira, Hideo
    Mikuniya, Megumi
    Okudera, Koichi
    Takanashi, Shingo
    Tasaka, Sadatomo
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S922 - S922
  • [3] A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer
    Tanaka, Hisashi
    Taima, Kageaki
    Morimoto, Takeshi
    Tanaka, Yoshihito
    Itoga, Masamichi
    Nakamura, Kunihiko
    Hayashi, Akihito
    Kumagai, Mika
    Yasugahira, Hideo
    Mikuniya, Megumi
    Okudera, Koichi
    Takanashi, Shingo
    Tasaka, Sadatomo
    BMC CANCER, 2017, 17
  • [4] Prognostic and predictive value of MET deregulation in non-small cell lung cancer
    Finocchiaro, Giovanna
    Toschi, Luca
    Gianoncelli, Letizia
    Baretti, Marina
    Santoro, Armando
    ANNALS OF TRANSLATIONAL MEDICINE, 2015, 3 (06)
  • [5] A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer
    Heather A. Wakelee
    Scott Gettinger
    Jeffrey Engelman
    Pasi A. Jänne
    Howard West
    Deepa S. Subramaniam
    Joseph Leach
    Michael Wax
    Yifah Yaron
    Dale R. Miles
    Primo N. Lara
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 923 - 932
  • [6] A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer
    Wakelee, Heather A.
    Gettinger, Scott
    Engelman, Jeffrey
    Janne, Pasi A.
    West, Howard
    Subramaniam, Deepa S.
    Leach, Joseph
    Wax, Michael
    Yaron, Yifah
    Miles, Dale R.
    Lara, Primo N., Jr.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (05) : 923 - 932
  • [7] A phase II study of paclitaxel in patients with non-small cell lung cancer
    Voravud, N
    Sriuranpong, V
    Foofung, S
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1111 - 1111
  • [8] A phase II study of vinorelbine in patients with advanced non-small cell lung cancer
    Evans, TRJ
    Mansi, JL
    Morgan, DAL
    Gyi, KM
    Banham, SW
    Milroy, R
    ONCOLOGY REPORTS, 1997, 4 (06) : 1337 - 1341
  • [9] PHASE II STUDY OF VINDESINE IN PATIENTS WITH NON-SMALL CELL LUNG-CANCER
    FUJITA, J
    SAIJO, N
    EGUCHI, K
    SHINKAI, T
    TOMINAGA, K
    SASAKI, Y
    FUTAMI, H
    SAKURAI, M
    ISHIHARA, J
    TAKAHASHI, H
    HOSHI, A
    JAPANESE JOURNAL OF CANCER RESEARCH, 1985, 76 (09): : 902 - 905
  • [10] Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer
    vonPawel, J
    Wagner, H
    Niederle, N
    Heider, A
    Koschel, G
    Hecker, D
    Hanske, M
    SEMINARS IN ONCOLOGY, 1996, 23 (06) : 47 - 50
12345